THERANEXUS EO -,25

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, THERANEXUS EO -,25 had revenue of €3.26M and net profit of -€100.39K

(EUR)	June 2026	YoY
Revenue	3.26M	-
Gross profit	1.09M	-
Net profit	-100.39K	-
EBITDA	-707.19K	-

Fundamentals

Metric	Value
Market capitalization	€47.78M
Number of shares	14.44M
52-week high/low	€5.10 - €1.49
Dividends	No
Beta	1.52
P/E ratio	-34.16
PEG ratio	-0.50
P/B ratio	16.13
P/S ratio	14.68

Company profile

Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.